% | $
Quotes you view appear here for quick access.

Epizyme, Inc. Message Board

  • davidwanj_00 davidwanj_00 Nov 15, 2013 10:36 AM Flag

    Citigroup Buy rating on epzm

    Epizyme (NASDAQ:EPZM) had its buy rating reissued by analysts at Citigroup Inc.. The firm currently has a $32.00 target price on the stock, down from their previous target price of $42.00. The analysts wrote, “We remain supportive of EPZM, while understanding of the initial stock reaction to early data from the P1 trial of their lead epigenetic drug, EPZ-5676, based on previously high expectations. Our assessment of the data is that it’s too early to form any conclusions; however, until further clarity on additional optimization is available, we are trimming our sales projections based on today’s results. We maintain our Buy rating on EPZM and are lowering our TP to $32 from $42.”

    SortNewest  |  Oldest  |  Most Replied Expand all replies
10.09+0.89(+9.67%)Jun 28 4:00 PMEDT